These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19805415)

  • 1. Rapamycin: the cure for all that ails.
    Hasty P
    J Mol Cell Biol; 2010 Feb; 2(1):17-9. PubMed ID: 19805415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity.
    Sharp ZD; Strong R
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554
    [No Abstract]   [Full Text] [Related]  

  • 3. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
    Subbiah IM; Brown RE; Fallon MB
    Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapamycin joins the aging fray: maybe Ponce de Leon visited Rapa Nui, not Florida.
    Sierra F
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):577-9. PubMed ID: 20410142
    [No Abstract]   [Full Text] [Related]  

  • 5. Functional consequences of mTOR inhibition.
    Sudarsanam S; Johnson DE
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
    Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?].
    Foster DA; Gadir N
    Ai Zheng; 2008 Aug; 27(8):882-4. PubMed ID: 18710627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [mTOR inhibitors].
    Oya M
    Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
    Richard DJ; Verheijen JC; Zask A
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):428-40. PubMed ID: 20597028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
    Ji J; Zheng PS
    Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2011 Aug; 14(4):437-41. PubMed ID: 21851176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [mTOR, the mammalian target of rapamycin].
    Julien LA; Roux PP
    Med Sci (Paris); 2010 Dec; 26(12):1056-60. PubMed ID: 21187044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
    Zakikhani M; Blouin MJ; Piura E; Pollak MN
    Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension.
    Mejias M; Garcia-Pras E; Gallego J; Mendez R; Bosch J; Fernandez M
    J Hepatol; 2010 Apr; 52(4):529-39. PubMed ID: 20206401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
    Grzmil M; Morin P; Lino MM; Merlo A; Frank S; Wang Y; Moncayo G; Hemmings BA
    Cancer Res; 2011 Mar; 71(6):2392-402. PubMed ID: 21406405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma].
    Li YL; Zhang X; Liu Y; Li SS; Xie L; Zhang N; Liu XB; Tian YQ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep; 45(9):765-8. PubMed ID: 21092676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease.
    Santos RX; Correia SC; Cardoso S; Carvalho C; Santos MS; Moreira PI
    J Neurochem; 2011 Jun; 117(6):927-36. PubMed ID: 21447003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.